₹55per share · Base Model Note
Revenue growth, the horizon and scenarios are yours to change. Every other input is part of the Trader plan; saving, sharing a saved link and the live-formula workbook are part of the Institutional plan.
Scenario
Value per share, your model₹55implied P/B 1.81× on FY26 book
Against CMP ₹39.13+39.8%close of 2026-09-10
Cost of equity12.02%risk-free + beta × equity risk premium
Book equity, FY26₹30per share · excess returns add ₹25
This figure is the arithmetic of your inputs and nothing else. MarketPing publishes no fair value, target or rating; the model is yours.
Excess-return schedule · ₹ crore · book equity earns your ROE; value is book plus the returns above the cost of equity
| ₹ crore | FY27 | FY28 | FY29 | FY30 | FY31 |
|---|---|---|---|---|---|
| Opening book equity | 21 | 24 | 28 | 33 | 38 |
| Net income at 16% ROE | 3 | 4 | 5 | 5 | 6 |
| Cost of equity charge at 12.02% | (3) | (3) | (3) | (4) | (5) |
| Excess return | 1 | 1 | 1 | 1 | 2 |
| Present value | 1 | 1 | 1 | 1 | 1 |
| Closing book equity | 24 | 28 | 33 | 38 | 44 |
| Book equity today | 21 |
| PV of 5 years of excess return | 4 |
| PV of the terminal excess return, 5% flat | 13 |
| add non-operating investments | 0 |
| Equity value | 38 |
| ÷ 0.70 crore shares | ₹55 |
Where the methods land · ₹ per share · the dashed line is the CMP
52-week rangetraded range, a fact not a value
₹35₹53
Scenarios side by side · ₹ per share
| Scenario | Template | Growth | Margin | Rate | Terminal | ₹ / share | vs CMP |
|---|---|---|---|---|---|---|---|
| Base · editing | Excess return | ROE 16% | — | 12.02% | 5% | ₹55 | 39.8% |
A scenario is a full set of inputs under a name. Keep Base as the filed history carried forward; add Bull and Bear by saving the current inputs under those names and moving the two or three assumptions you actually hold a view on. The distribution above draws each driver between the lowest and highest value across your scenarios, so three scenarios give it a real range; with one scenario it falls back to fixed bands.